Table 1 Baseline predictors and outcomes in the Emirati validation and Framingham cohorts
Characteristic | Emirati validation cohort (n = 554) | Framingham study cohort* (n = 5251) | P-value† |
|---|---|---|---|
Age (years), mean (SD) | 48.0 (12.8) | 49.0 (NA) | |
Men, n (%) | 249 (44.9) | 2439 (46.4) | 0.502 |
Blood pressure, n (%) | |||
Normal and prehypertension | 408 (73.7) | 3558 (67.7) | < 0.001 |
Stage 1 HTN | 116 (20.9) | 1095 (20.9) | |
Stage 2 HTN | 30 (5.4) | 598 (11.4) | |
TC, mmol/L, n (%) | |||
< 5.17 | 298 (53.8) | 1996 (38.0) | < 0.001 |
5.17–6.18 | 166 (30.0) | 1879 (35.8) | |
≥ 6.20 | 90 (16.2) | 1376 (26.2) | |
HDL-C, mmol/L, n (%) | |||
≤ 1.53 | 482 (87.0) | 3829 (72.9) | < 0.001 |
≥ 1.55 | 72 (13.0) | 1422 (27.1) | |
Smoking history, n (%) | 102 (18.4) | 2045 (38.9) | < 0.001 |
Diabetes mellitus, n (%) | 0 (0.0)‡ | 234 (4.5) | < 0.001 |
Observed hCHD events, n (%) | 26 (4.7) | 273 (5.2) | |